Treatment of Intermittent Claudication by G-CSF-mobilized PB-MNC
Treatment of Intermittent Claudication by G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Nuttawut Sermsathanasawadi, MD, PhD
- Phone Number: +6624198021
- Email: nuttawut@gmail.com
Study Locations
-
-
Bangkok
-
Bangkoknoi, Bangkok, Thailand, 10700
- Recruiting
- Faculty of Medicine, Siriraj Hospital, Mahidol University
-
Contact:
- Nuttawut SERMSATHANASAWADI
- Phone Number: +6624198021
- Email: nuttawut@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with chronic arterial occlusive disease who presented with intermittent claudication
Exclusion Criteria:
- Recent myocardial infarction
- Severe valvular heart disease
- After organ transplantation
- Cardiomyopthy( EF< 25%)
- Liver failure
- Coagulopathy
- HIV
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: PB-MNC therapy
The patientsin PB-MNC therapy group will be injected with G-CSF mobilized PB-MNC into calf or thigh muscle of ischemic limb, Aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.
|
The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day.
The mononuclear cell will be collected by blood cell separator.
The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge.
Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
|
|
Active Comparator: No PB-MNC therapy
In patients in No PB-MNC therapy, they will receive aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.
|
Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain free walking distance
Time Frame: 3 month
|
the maximum distance which patient could walk without pain
|
3 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ankle brachial index (ABI)
Time Frame: 1,3,6,12 month
|
Ankle brachial indexThe Ankle Brachial Index (ABI) is the systolic pressure at the ankle, divided by the systolic pressure at the arm.
It has been shown to be a specific and sensitive metric for the diagnosis of Peripheral Arterial Disease (PAD)
|
1,3,6,12 month
|
|
Toe brachial index (TBI)
Time Frame: 1,3,6,12 month
|
Toe brachial indexThe toe brachial index is the ratio between toe pressure and the highest of the two brachial pressures
|
1,3,6,12 month
|
|
Transcutaneous oxygen measurement (TCOM)
Time Frame: 1,3,6,12 month
|
Transcutaneous oxygen measurement
|
1,3,6,12 month
|
|
36-Item Short Form Health Survey (SF36)
Time Frame: 1,3,6,12 month
|
SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.
These measures rely upon patient self-reporting.
|
1,3,6,12 month
|
|
Pain free walking distance
Time Frame: 1,6,12 month
|
the maximum distance which patient could walk without pain
|
1,6,12 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nuttawut SERMSATHANASAWADI, MD, PhD, Mahidol university
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SI016033012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.